Related Experiment Video
Updated: Mar 1, 2026
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
9.5K
Modified rifampin nanoparticles: Increased solubility with slow release Rate.
Poopak Farnia1, Ali Akbar Velayati2, Saeed Mollaei3
1Mycobacteriology Research Center, National Research Institute of Tuberculosis and Lung Disease, (NRITLD), Shahid Beheshti University of Medical Sciences; Department of Biotechnology, School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
International Journal of Mycobacteriology
|June 1, 2017
Summary
Researchers developed novel rifampin nanoparticles (RIF-NPs) using chitosan, gelatin, and lecithin. These RIF-NPs demonstrate enhanced loading capacity and a slow-release profile, offering a promising approach for improved drug delivery.
Area of Science:
- Nanotechnology
- Materials Science
- Pharmacology
Background:
- Nanotechnology-based drug delivery systems enhance antibacterial efficacy and pharmacokinetics.
- Designing effective drug carriers is crucial for improving therapeutic outcomes.
- Rifampin nanoparticles (RIF-NPs) aim for high loading capacity and slow release.
Purpose of the Study:
- To design and characterize rifampin nanoparticles (RIF-NPs) with optimized loading capacity and slow release.
- To investigate the influence of lecithin concentration on RIF-NP properties.
- To evaluate the drug release profile of RIF-NPs under different pH conditions.
Main Methods:
- Chitosan/gelatin/lecithin (Chg/L) RIF-NPs were prepared using a multilamellar vesicle method.
- Particle size, zeta potential, morphology, and drug release rate were analyzed.
- Lecithin concentration was varied to optimize loading capacity and release profiles.
Main Results:
- Lecithin concentration correlated significantly with NP size, zeta potential, and loading capacity.
- Increased lecithin (0.2-2.0 g) reduced NP size (250-150 nm) and increased zeta potential (14-49 mV) and loading capacity (8-20%).
- RIF-NPs exhibited a slow drug release profile, influenced by pH and lecithin concentration, outperforming standard drug release.
Conclusions:
- The developed Chg/L-RIF NPs demonstrate a promising slow and constant rifampin release rate.
- This controlled release mechanism may effectively eliminate bacilli and prevent the development of rifampin-resistant strains.
- These nanoparticles represent a promising nanocarrier for enhanced drug delivery applications.
Related Concept Videos
01:16Bioavailability Enhancement: Drug Solubility Enhancement
365
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
365
01:20Modified-Release Drug Delivery Systems: Influencing Factors
84
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
84
01:30Modified-Release Drug Delivery Systems: Bioavailability
60
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
60
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.8K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.8K
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
56
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
56
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
284
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
284